Skip Navigation

infoSIDA logo

 
Home > Drugs > Delavirdine

Delavirdine Delavirdine
Click Image to Enlarge

de-la-VIR-deen   Audio

Brand Name: Rescriptor  Audio
Drug Class: Non-nucleoside Reverse Transcriptase Inhibitors
Delavirdine, also known as Rescriptor, is a type of medicine called a non-nucleoside reverse transcriptase inhibitor (NNRTI). NNRTIs block reverse transcriptase, a protein that HIV needs to make more copies of itself.

HIV/AIDS-Related Uses
Delavirdine was approved by the FDA on April 4, 1997, for use with other antiretroviral medications in the treatment of HIV infection in adults. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.

Dosage Form/Administration
Delavirdine comes in tablet form and is taken by mouth. Avoid taking delavirdine within 1 hour of taking didanosine (Videx or ddI) or antacids. Delavirdine tablets (in the 100 mg dosing form only) may be dissolved in water if patients are unable to swallow pills.

Recommended Daily Dose
The recommended dose of delavirdine for adults is 400 mg (four 100 mg or two 200 mg tablets) three times a day. Some patients may benefit from different doses of delavirdine. Patients should always take delavirdine as prescribed by their doctor.

Contraindications
Individuals should tell a doctor about any medical problems before taking this medicine. Certain medications may affect the functioning of the liver; patients taking these medications or who have liver disease should not take delavirdine.

Possible Side Effects
Along with its desired effects, delavirdine can cause some unwanted effects. Serious side effects of this medicine include severe skin rash accompanied by blisters, fever, joint or muscle pain, redness and swelling of the eyes, sores in the mouth, and swelling; serious kidney problems; anemia; and liver and muscle problems. Individuals should tell a doctor if they have any of these side effects.
Other side effects may not be serious and may lessen or disappear with continued use of the medicine. Many people who take delavirdine report having rash on the upper body and arms within the first 1 to 3 weeks they are taking the medication. This rash usually goes away within about 2 weeks. Other less serious side effects of this medicine include diarrhea, nausea, vomiting, unusual tiredness, and headache. Individuals should tell a doctor if these side effects continue or are bothersome.

Drug and Food Interactions
A doctor should be notified of any other medications being taken, including prescription, nonprescription (over-the-counter), or herbal medications.

Clinical Trials
Click here to search ClinicalTrials.gov for trials that use Delavirdine.

Manufacturer Information
Delavirdine
  Pfizer Inc
  235 East 42nd Street
  New York,  NY  10017-5755
  (800) 438-1985
    

Rescriptor
  Pfizer Inc
  235 East 42nd Street
  New York,  NY  10017-5755
  (800) 438-1985
    
Updated January 31, 2007